摘要
目的探讨行经皮冠状动脉介入治疗(PCI)术中冠脉内应用替罗非班对急性心肌梗死患者血清超敏C反应蛋白(hs-CRP)和可溶性CD40配体(sCD40L)的影响。方法行PCI手术的82例急性心肌梗死患者随机分为两组,对照组40例,治疗组42例;对照组采用常规治疗,治疗组在行PCI术中冠脉内注射替罗非班。观察PCI术后的血流,血清hs-CRP和sCD40L。结果梗死相关冠脉血流(TIMI)达到3级的对照组33例,治疗组40例,两组有统计学差异(P<0.05)。两组在治疗后均明显改善了患者血清hs-CRP和sCD40L,并且治疗组改善更加明显(P<0.05),具有统计学意义。结论 PCI术中冠脉内使用替罗非班可以明显改善急性心肌梗死患者的血流,减少血清hs-CRP和sCD40L的表达。
Objective To study the effectiveness of intracoronary injection of tirofiban on high sensitivity C-reactive protein（hs-CRP） and soluble CD40 ligand（sCD40L） on patients with acute myocardial infarction.Methods Eighty-two patients with acute myocardial infarction through percutaneous coronary intervention（PCI） were randomly divided into two groups,the control group（n=40 cases） and the treatment group（n=42 cases）.The patients in the control group were treated through the conventional treatment and the patients in the treatment group were treated through intracoronary injection of tirofiban.The thrombolysis in myocardial infarction（TIMI）,hs-CRP and sCD40L were compared.Results The patients whose TIMI was more than three class were 33 cases in the control group and 40 cases in the treatment group.There was a significant difference（P0.05）.The hs-CRP and sCD40L in the serum were all lowed after treatment in both groups.The hs-CRP and sCD40L in the treatment were improved significantly more than those of the control group（P0.05）.Conclusion Intracoronary injection of tirofiban through PCI can improve thrombolysis,descrease hs-CRP and sCD40L.
出处
《中国实用医药》
2012年第22期40-41,共2页
China Practical Medicine
